Standard dosage and injection frequency of Tarlatamab

Tarlatamab (Tarlatamab) is a novel bispecific Tcell connector (BiTE) that targets DLL3 (Delta-like ligand 3) and CD3 molecules, mainly used to treat small cell lung cancer (SCLC) that expresses DLL3. It guides the patient's own T cells to accurately identify and kill tumor cells. It is an innovative therapy with immunotherapy properties. In clinical applications, the administration mode and frequency of talatumumab are precisely designed to balance efficacy and safety.

Based on clinical study data, talatumumab is typically administered by intravenous infusion. The standard dose varies slightly in different research phases, but the common recommended dose in Phase II studies is once every 3 weeks (21 days), with each dose of 10 mg. The treatment cycle is adjusted according to patient response and tolerance. Infusions usually need to be performed at a medical institution with experience in cancer immunotherapy so that possible infusion reactions can be monitored.

In the early stages of administration, doctors usually implement pretreatment measures, such as antihistamines, antipyretic analgesics, or steroids, to reduce the risk of immune-related side effects such as cytokine release syndrome (CRS). On the day of the injection, the patient needs to stay in the hospital for several hours to ensure there are no obvious adverse reactions before leaving. As the patient's tolerance of the drug improves, subsequent treatments can be maintained at the regular frequency of injections, continuing every three weeks.

In general, the standard dosage of talatumumab is 10mg once every three weeks by intravenous injection. The treatment cycle and injection frequency can be adjusted according to individual response. Patients should closely cooperate with their doctors during treatment and regularly check liver and kidney function, immune cell levels and tumor indicators to ensure that the treatment is safe and effective. As more clinical data is released, the drug's dosage regimen may be further optimized to improve efficacy and reduce side effects.

Reference materials:https://www.drugs.com